Oncology novel active substance (NAS) launches (annual) vs Cell and gene therapy venture capital and public funding deal count
Oncology novel active substance (NAS) launches (annual) and Cell and gene therapy venture capital and public funding deal count worldwide, compared over time.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Oncology novel active substance (NAS) launches (annual) and Cell and gene therapy venture capital and public funding deal count
Unit: count · 6 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Oncology novel active substance (NAS) launches (annual) | 2024 | Actual | 25 |
| Oncology novel active substance (NAS) launches (annual) | 2020–2024 | Actual | 26 |
| Oncology novel active substance (NAS) launches (annual) | 2015–2019 | Actual | 16 |
| Cell and gene therapy venture capital and public funding deal count | 2023 | Actual | 96 |
| Cell and gene therapy venture capital and public funding deal count | 2022 | Actual | 97 |
| Cell and gene therapy venture capital and public funding deal count | 2021 | Actual | 127 |
Provenance
Where these numbers come from
Oncology novel active substance (NAS) launches (annual)
Annual number of oncology novel active substances launched, for a single year or averaged across years.
3 observations in Global · source organisations: IQVIA
Cell and gene therapy venture capital and public funding deal count
Number of venture capital and public funding transactions for cell and gene therapies in a given year.
3 observations in Global · source organisations: IQVIA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring